title: The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes.
abstract: Pathological aggregation of the microtubule-associated protein tau and subsequent accumulation of neurofibrillary tangles (NFTs) or other tau-containing inclusions are defining histopathological features of many neurodegenerative diseases, which are collectively known as tauopathies. Due to conflicting results regarding a correlation between the presence of NFTs and disease progression, the mechanism linking pathological tau aggregation with cell death is poorly understood. An emerging view is that NFTs are not the toxic entity in tauopathies; rather, tau intermediates between monomers and NFTs are pathogenic. Several proteins associated with neurodegenerative diseases, such as β-amyloid (Aβ) and α-synuclein, have the tendency to form pore-like amyloid structures (annular protofibrils, APFs) that mimic the membrane-disrupting properties of pore-forming protein toxins. The present study examined the similarities of tau APFs with other tau amyloid species and showed for the first time the presence of tau APFs in brain tissue from patients with progressive supranuclear palsy (PSP) and dementia with Lewy bodies (DLB), as well as in the P301L mouse model, which overexpresses mutated tau. Furthermore, we found that APFs are preceded by tau oligomers and do not go on to form NFTs, evading fibrillar fate. Collectively, our results demonstrate that in vivo APF formation depends on mutations in tau, phosphorylation levels, and cell type. These findings establish the pathological significance of tau APFs in vivo and highlight their suitability as therapeutic targets for several neurodegenerative tauopathies.
authors.forename: Cristian A
authors.initials: CA
authors.lastname: Lasagna-Reeves
authors.forename: Urmi
authors.initials: U
authors.lastname: Sengupta
authors.forename: Diana
authors.initials: D
authors.lastname: Castillo-Carranza
authors.forename: Julia E
authors.initials: JE
authors.lastname: Gerson
authors.forename: Marcos
authors.initials: M
authors.lastname: Guerrero-Munoz
authors.forename: Juan C
authors.initials: JC
authors.lastname: Troncoso
authors.forename: George R
authors.initials: GR
authors.lastname: Jackson
authors.affiliation: Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA. rakayed@utmb.edu.
authors.forename: Rakez
authors.initials: R
authors.lastname: Kayed
mesh_terms: D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D022082:Cellular Structures / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D047468:Immunoprecipitation; D020961:Lewy Body Disease / Q000473:pathology*; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation / Q000235:genetics; D004676:Myelin Basic Protein / Q000378:metabolism; D009447:Neuroblastoma / Q000473:pathology; D010766:Phosphorylation / Q000502:physiology; D013494:Supranuclear Palsy, Progressive / Q000473:pathology*; D016875:tau Proteins / Q000737:chemistry* / Q000378:metabolism*
chemical_list: D004676:Myelin Basic Protein; D016875:tau Proteins